What Calperos Treats: Main Uses and Benefits

Calperos, which contains calcium carbonate, is considered relevant in managing calcium deficiency and for easing symptoms related to physical discomfort like indigestion. Calcium carbonate is commonly used to help with conditions characterized by periods of heightened symptoms of calcium deficiency, such as those related to physical discomfort or systemic imbalance. It may be part of symptomatic management for conditions presenting with acute episodes of calcium deficiency, and it may assist with maintaining functional stability in conditions like osteoporosis.

The active ingredient is applied across two core therapeutic domains: managing calcium deficiency and easing symptoms related to physical discomfort like indigestion. It is relevant for easing symptoms related to physical discomfort such as heartburn, acid indigestion, and upset stomach. This supports patients during episodes of heightened discomfort and contributes to easing the overall symptom load for patients requiring either supplemental calcium or short-term symptomatic assistance.

“This supports patients during episodes of heightened discomfort and may assist with maintaining functional stability.”

Quick Fact: Relevant for Managing Digestive Discomfort and Systemic Imbalance

Regulatory References

1. Calcium Carbonate: MedlinePlus Drug Information

Who Can and Cannot Use Calperos?

Eligibility for Calperos, a combination of Calcium Carbonate and Cholecalciferol (Vitamin D3), is governed by official regulatory documents that strictly define permitted use, restrictions, and absolute prohibitions.

Approved and Restricted Populations

The medicine is officially approved for use in the adult and elderly populations. Use in children and adolescents is generally not recommended or, for certain high-dose formulations, is contraindicated.

For pregnant or breastfeeding women, use is permitted but conditional on maintaining strict daily intake limits of calcium and Vitamin D as defined in the product labeling, to avoid potential overdose.

Absolute Contraindications (Must Not Use)

Calperos is formally contraindicated (prohibited) in patients with pre-existing conditions that affect mineral balance or kidney function. These contraindications include:

• Hypercalcaemia (abnormally high blood calcium) or Hypervitaminosis D (Vitamin D overdose).
• Severe renal impairment or a history of nephrolithiasis (kidney stones).
• Diseases leading to high calcium levels, such as myeloma or bone metastases.
• Known hypersensitivity to the active substances or excipients.

Use is also conditional and requires caution and specialized monitoring for individuals with sarcoidosis or non-severe renal impairment, where risks of mineral imbalance are elevated.

Interactions with other medicines and products

Co-administration of Calperos (Calcium Carbonate/Cholecalciferol) with specific medicines and substances results in documented interactions that necessitate regulatory restrictions. The predominant interaction is gastrointestinal absorption interference, where the calcium component binds to and officially reduces the systemic exposure of other drugs.

Documented Interaction Patterns

• Exposure-Modifying Agents: Regulatory labeling identifies numerous agents whose absorption is impaired, including Tetracycline and Quinolone antibiotics, Levothyroxine (thyroid hormones), Bisphosphonates, Strontium, and Iron salts. To mitigate this reduction in exposure, official regulatory timing rules require that co-administration be separated by specific intervals ranging from two to six hours, depending on the interacting agent.
• Pharmacodynamic and Metabolic Interactions: Combination use with Cardiac Glycosides or Thiazide Diuretics is officially documented to increase the risk of hypercalcaemia due to an additive effect on calcium homeostasis, necessitating close patient monitoring. Furthermore, enzyme-inducing agents like Phenytoin and Barbiturates are known to accelerate the metabolic breakdown of the Vitamin D component, which officially leads to a decreased pharmacological effect.
• Substance Restrictions and Cautions: Official warnings exist concerning the consumption of foods high in oxalic acid or phytic acid as they reduce calcium absorption. Likewise, substances such as mineral oil and cholestyramine are documented to impair the absorption of Vitamin D. Caution is also noted in official labeling for use in patients with renal insufficiency and sarcoidosis due to altered calcium metabolism.

Mineral Supply and Bioavailability

This domain covers the delivery of elemental calcium ( Ca^2+) ions and the co-factor Vitamin D3 to the bloodstream. The mechanism primarily involves gastrointestinal dissolution and absorption, increasing the concentration of mineral substrate available for systemic transport.

Vitamin D-Mediated Pathway Regulation

This core mechanistic domain is driven by Vitamin D3's conversion to its active hormonal form, which activates the Vitamin D Receptor (VDR). VDR activation acts on gene transcription, upregulating intestinal calcium transport and modulating the activity of osteoblasts and osteoclasts, which impacts bone turnover and systemic calcium regulation.

Skeletal Maintenance and Homeostasis Support

This mechanism focuses on the final destination and function of the absorbed calcium and the modulated bone cell activity. This domain contributes directly to the incorporation of mineral into the bone matrix and calcium retention within the skeletal structure.

Administration Scope

Calperos is intended for oral administration. The preparation is supplied in various dosage forms, including hard capsules and chewable tablets, with the method of consumption depending on the specific form. Chewable tablets must be chewed or sucked to aid disintegration before swallowing, while hard capsules should be swallowed whole with water.

Dosing and Frequency Patterns

The standard adult dosing regimen is designed to achieve a total daily intake of elemental calcium typically ranging between 800 mg and 1200 mg, depending on the specific product formulation. This intake is generally managed through divided use, often specified as a twice-daily schedule (e.g., morning and evening), to enhance bioavailability.

Administration is generally advised to occur with a meal to support optimal calcium absorption. If a dose is missed, it is generally recommended to take only the next scheduled dose at the appropriate time and not to take a double dose.

Use Patterns and Procedural Conditions

The preparation is frequently used as part of a long-term treatment plan. Dosage for older adults typically follows the standard adult regimen, while pediatric use is defined by a lower, age-appropriate daily maximum dose. During long-term use, the dosage may require individualization based on laboratory monitoring of serum and urinary calcium levels.

Recent Clinical Evidence Overview

Calperos is a brand name for a combination therapy containing calcium carbonate (a calcium salt) and cholecalciferol (Vitamin D3). This combination is typically studied in the context of managing or preventing calcium and Vitamin D deficiencies, particularly in older adults, and as an adjunct to treatments for osteoporosis.

Efficacy in Bone Health

Clinical trials focusing on calcium and Vitamin D co-supplementation have investigated outcomes related to bone mineral density (BMD) and fracture risk. The landmark Women’s Health Initiative (WHI) trial, which studied over 36,000 postmenopausal women, found that daily supplementation with 1,000 mg of elemental calcium (as carbonate) and 400 IU of Vitamin D3 did not significantly reduce hip fracture rates in the overall study population during the intervention phase. However, analysis suggested that the supplements did help preserve total hip BMD.

Other meta-analyses and trials, particularly those involving subjects with clear baseline deficiencies or institutionalized elderly, have reported that the combination of calcium and Vitamin D may be associated with a reduced relative risk of hip and non-vertebral fractures compared to placebo, though study designs and population characteristics varied widely.

Safety Considerations

Long-term data from the WHI and other systematic reviews have raised safety considerations for combination supplementation. After extended follow-up, the WHI trial reported a slightly increased risk of death from cardiovascular disease and a reduced risk of death from cancer in the combination group. Additionally, supplementation with calcium and Vitamin D has been consistently associated with an increased incidence of kidney stones in multiple randomized controlled trials. These mixed findings underscore the importance of assessing individual patient risk factors and baseline nutritional status before initiating long-term therapy.

How to Store and Dispose of Calperos

The storage of Calperos must comply with official labeling to preserve its quality. The medication must not be stored above 25 °C and requires protection from moisture and excess heat. It is critical that the product is never frozen and is always kept in its original, tightly closed container.

Child Safety and Disposal

To prevent accidental ingestion, Calperos must be kept out of the sight and reach of children, and safety caps should be locked where applicable. Do not use the product past the expiry date printed on the packaging.

Official disposal regulations prohibit discarding the medicine through wastewater or household waste. Unused or expired medication should be disposed of by consulting a pharmacist or local collection program for proper adherence to national guidelines.